Efficacy and safety of integrated Chinese and Western medicine in advanced pancreatic cancer: A double-center retrospective cohort study

Table 1 Patient characteristics, n (%)

Characteristics	Integration of Chinese and Western medicine group (n = 66)	Western medicine group (n = 70)	χ2	P value
Gender			0.002	0.968
Female	29 (43.9)	31 (44.3)
Male	37 (56.1)	39 (55.7)
Age (years)			0.485	0.486
< 65	36 (54.5)	34 (48.6)
≥ 65	30 (45.5)	36 (51.4)
Eastern Cooperative Oncology Group Performance Status			2.483	0.115
0 and 1	45 (68.2)	56 (80.0)
2	21 (31.8)	14 (20.0)
Histological type			0.709	0.400
Ductal adenocarcinoma	62 (93.9)	63 (90.0)
Other	4 (6.1)	7 (10.0)
Differentiation grade			2.566	0.277
Poorly differentiated	50 (75.8)	46 (65.7)
Moderately differentiated	15 (22.7)	20 (28.6)
Well differentiated	1 (1.5)	4 (5.7)
Primary site			5.005	0.171
Head of pancreas	36 (54.5)	51 (72.9)
Body of pancreas	4 (6.1)	3 (4.3)
Tail of pancreas	11 (16.7)	7 (10.0)
Mixed	15 (22.7)	9 (12.9)
TNM stage			0.636	0.425
Stage III	11 (16.7)	12 (17.1)
Stage IV	55 (83.3)	58 (82.9)
Ascites presence
Present	8 (12.1)	8 (11.4)
Absent	58 (87.9)	62 (88.6)
Hepatic impairment
Present	39 (59.1)	46 (65.7)
Absent	27 (40.9)	24 (34.3)
Treatment regimen			6.464	0.167
Chemotherapy	48 (72.7)	50 (71.4)
Chemotherapy plus targeted therapy	4 (6.1)	2 (2.9)
Chemotherapy plus immunotherapy	1 (1.5)	8 (11.4)
Radiofrequency ablation	6 (9.1)	5 (7.1)
Radioactive seed implantation brachytherapy	7 (10.6)	5 (7.1)